CorMatrix launches U.S. tricuspid valve device trial

This study actively addresses the need for a tricuspid valve replacement that improves clinical outcomes in pediatric and adult patients who may not otherwise have an option. The development of this application of CorMatrix ECM Technology truly has the capacity to lengthen people lives and furthers our pursuit of developing the best possible medical devices for surgeons and the patients they treat,” CEO David Camp said in a press release. The 1st operation was performed by Dr. Marc Gerdisch of Indianapolis, Ind.’s Franciscan St. Francis Health, the company said. “The past decade has seen an enormous expansion of research in, and subsequently—understanding of extracellular matrix. We have been using CorMatrix for 8 years with remarkable success in reconstructing complex structures of the heart and blood vessels. In 2014, we published the North American experience with complete CorMatrix tubular reconstruction of the tricuspid valve. Given the remarkable adaptability and regenerative properties of CorMatrix we recognized the dramatic effect this could have on surgery for tricuspid valve pathology, especially for younger patients. Furthermore, it would serve as a platform for engineering other heart valves. This 1st FDA study enrollment is a substantial step toward patients avoiding synthetic replacement valves by having the opportunity to regrow their own,” Dr. Gerdisch said in prepared remarks. The study is slated to enroll up to 16 patients who are...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiac Implants Cardiovascular Clinical Trials Regenerative Medicine CorMatrix Cardiovascular Inc. Source Type: news